



PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



Ref: PDL: SCY: AUG: 2011-2012

Dated: August 13, 2011

To
The National Stock Exchange of India Limited
"Exchange Plaza",
Bandra-Kurla Complex,
Bandra (East), Mumbai, Maharashtra

SUBJECT: COMPLIANCE OF CLAUSE 41 AND CLAUSE 20 OF THE LISTING AGREEMENT.

Dear Sir,

Pursuant to Clause 41 and Clause 20 of the Listing Agreement, please find enclosed herewith the following:

- 1) Audited financial results of the Company for the financial year 2010-2011 duly approved by the Board of Directors in its meeting held on 13th August, 2011
- 2) Unaudited financial results of the Company for the quarter ended 30th June, 2011 duly approved by the Board of Directors in its meeting held on 13th August, 2011

Further, the Board of Directors has recommended dividend @ Rs.0.50 per share on fully paid up equity shares of the Company for the year 2010-2011 in its meeting held on 13th August, 2011

You are requested to take the above said information on your record and oblige.

Thanking You,

Yours Faithfully,
For Parabolic drugs Limited


(Vipin Gupta)
Company Secretary

Regd. Office : S.C.O. 99 - 100, 3rd & 4th Floor, Sector 17 - B,
Chandigarh - 160 017 (India)
Tel. : +91-172-3914646, 3914647 Fax : +91-172-3914645
Corp. Office : 9 AB, Taimoor Nagar, New Friends Colony,
New Delhi (India)
Tel. : +91-11-64510543, 26332660

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India
Telefax : (01762) 280305
Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India
Tel. : +91-172-2591443
R & D Centre : 280-281, HSIIDC, Tehsil Barwala,
District Panchkula (Hry.) India Tel. : +91-1733-256380

website : www.parabolicdrugs.com

**AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2011 FOR
REVIEW OF AUDIT COMMITTEE MEETING ON 13 AUGUST 2011**

Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh
Corporate Office: 9 AB, Taimoor Nagar, New Friends Colony, New Delhi
Audited Financial Results for the Year Ended 31st March, 2011

(Rs. Crores)

Particulars	Year ended 31/03/2011	Corresponding Previous Year Ended 31/03/2010
	Audited	Audited
a) Gross Sales	675.30	559.01
Less : Excise Duty	(59.28)	(45.12)
Net Sales/Income from Operations	616.02	513.89
(b) Other Operating Income	19.16	4.87
1. Total Income	635.18	518.76
2. Expenditure		
a) (Increase)/Decrease in stock in trade and work in progress	(89.78)	(52.06)
b) Consumption of Raw Materials	541.09	419.92
c) Employees Cost	16.93	13.90
d) Depreciation & Amortisations	17.69	10.07
e) Other Expenditure	39.81	35.31
f) Total	525.74	427.14
3. Profit from Operations before Other Income, Interest & Exceptional Items	109.44	91.62
4. Other Income		
5. Profit before Interest & Exceptional Items (3 + 4)	109.44	91.62
6. Interest	40.76	47.59
7. Profit after interest but before Exceptional Items (5-6)	68.68	44.03
8. Exceptional Items		
9. Profit (+)/Loss(-) from Ordinary Activities before tax (7 + 8)	68.68	44.03
10. Tax expenses	15.81	9.83
11. Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9 - 10)	52.87	34.20
12. Extra Ordinary Items		
13. Net Profit (+)/ Loss(-) for the period (11-12)	52.87	34.20
14. Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	37.25
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	317.11	121.37
16. Earnings Per Share (EPS)		
- Basic EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	9.43	17.91
- Diluted EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	9.43	17.91
- Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	9.43	17.91
- Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	9.43	17.91
17. Public Shareholding :		
- Number of Shares	38257907	13706029
- Percentage of Shareholding	61.81	36.79
18. Promoters and Promoter Group Shareholding (non-encumbered) :		
- Number of shares	23634107	23545020
- Percentage of shares (as a % of the to total shareholding of promoter and promoter group)	100.00	100.00
- Percentage of shares (as a % of the to total share capital of the company)	38.19	63.21



Consolidated figures of the Company and its subsidiaries for the year :		
Consolidated Net Sales / Income from operations & other Income	635.19	518.75
Consolidated Net Profit	52.87	34.19
Consolidated EPS	9.43	17.91
STATEMENT OF ASSETS & LIABILITIES :		
SOURCES OF FUNDS :		
SHAREHOLDERS' FUNDS		
Share Capital	61.89	37.25
Reserves & Surplus	317.11	121.36
LOAN FUNDS	474.40	420.69
DEFFERED TAX	9.75	7.63
TOTAL	863.15	586.93
APPLICATION OF FUNDS :		
FIXED ASSETS	275.21	170.89
INVESTMENTS	5.67	1.99
(A) CURRENT ASSETS LOANS & ADVANCES		
Inventories	340.65	240.11
Sundry Debtors	258.06	193.05
Cash & Bank	25.80	17.61
Loans & Advances	70.80	28.96
(B) CURRENT LIABILITIES & PROVISIONS		
NET CURRENT ASSETS (A) - (B)	491.21	103.24
MISC. EXPENDITURE	91.06	37.56
TOTAL	863.15	586.93

Notes :

1. The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 13th August 2011.
2. During the year the Company has : Filed eight Drug Master Files (DMF) with USFDA, one Canadian DMF, nine Certificate of Suitability (COS) with EDQM and seven process patent for Non-beta molecule with Indian Patent Office.
3. There were no investor complaint pending at the beginning of the financial year 2010-11. Twenty investor complaints received during of the year. No investor complaint was pending at the end of the year.
4. The company operates in only one Business Segment.
5. Figures of the previous year have been rearranged/regrouped wherever necessary.

For Parabios Pharmaceuticals Ltd.

Place : Chandigarh
Date : 13th August, 2011

Pranay Gupta
Mg. Director

Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh

Corporate Office: 9 AB, Taimoor Nagar, New Friends Colony, New Delhi


Unaudited Financial Results for the Quarter Ended 30th June, 2011

(Rs. Crores)

Particulars	Quarter ended 30/06/2011	Corresponding Quarter in the previous year ended 30/06/2010	Year ended 31/03/2011
	Unaudited	Unaudited	Audited
a) Gross Sales	205.47	140.15	675.30
Less : Excise Duty	(19.28)	(12.67)	(59.28)
Net Sales/Income from Operations	186.19	127.48	616.02
(b) Other Operating Income	2.68	0.32	19.16
1. Total Income	188.87	127.80	635.18
2. Expenditure			
a) (Increase)/Decrease in stock in trade and work in progress	(64.83)	(16.19)	(89.78)
b) Consumption of Raw Materials	198.37	106.46	541.09
c) Employees Cost	4.73	3.46	16.93
d) Depreciation & Amortisations	7.75	4.35	17.69
e) Other Expenditure	8.80	8.33	39.81
f) Total	154.82	106.41	525.74
3. Profit from Operations before Other Income, Interest & Exceptional Items	34.06	21.39	109.44
4. Other Income			
5. Profit before Interest & Exceptional Items (3 + 4)	34.06	21.39	109.44
6. Interest	14.14	7.89	40.76
7. Profit after interest but before Exceptional Items (5-6)	19.92	13.50	68.68
8. Exceptional Items	-	-	-
9. Profit (+)/Loss(-) from Ordinary Activities before tax (7 + 8)	19.92	13.50	68.68
10. Tax expenses	4.73	2.97	15.81
11. Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9 - 10)	15.18	10.53	52.87
12. Extra Ordinary Items			
13. Net Profit (+)/ Loss(-) for the period (11-12)	15.18	10.53	52.87
14. Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	61.89	61.89
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	317.11
16. Earnings Per Share (EPS)			
- Basic EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.45	2.77	9.43
- Diluted EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.45	2.77	9.43
- Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.45	2.77	9.43
- Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.45	2.77	9.43
17. Public Shareholding :			
- Number of Shares	38257907	38346994	38257907
- Percentage of Shareholding	61.81	61.96	61.81
18. Promoters and Promoter Group Shareholding (non-encumbered) :			
- Number of shares	23634107	23545020	23634107
- Percentage of shares (as a % of the to total shareholding of promoter and promoter group)	100.00	100.00	100.00
- Percentage of shares (as a % of the to total share capital of the company)	38.19	38.04	38.19

Notes :

1. The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 13th August 2011 and the same are subject to Limited Review by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.



2. During the period the Company has : Filed one Drug Master Files (DMF) with USFDA for one of its Non-Beta Lactum Products, one Certificate of Suitability (COS) with EDQM and one patent for Non-beta molecule with Indian Patent Office.

3. There were no investor complaints pending at the beginning of the quarter. No complaint received from the shareholders during the quarter and no complaint was pending at the end of the quarter.

4. The above financial results are on stand alone basis.

5. The company operates in only one Business Segment.

6. Figures of the previous year have been rearranged/regrouped wherever necessary.

For Parabolic Drugs Ltd.
For Parabolic Drugs Ltd.

Place : Chandigarh
Date : 13th August, 2011

N. Pragnav Gupta
Managing Director